Literature DB >> 7625109

Mucosal immunoadjuvant activity of liposomes: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes.

A de Haan1, H J Geerligs, J P Huchshorn, G J van Scharrenburg, A M Palache, J Wilschut.   

Abstract

This paper reports on a novel immunoadjuvant activity of liposomes. An influenza subunit preparation, containing the isolated viral surface antigens, was incorporated in a liposomal formulation. Administration of this vaccine to mice via the intranasal (i.n.) route resulted in a stimulated serum IgG response relative to the response to i.n. immunization with the antigen alone. In addition, the liposomal vaccine induced a secretory IgA (sIgA) response in the mucosa of the lungs and nasal cavity. Both serum IgG and sIgA responses persisted up to at least 21 weeks postimmunization. Immune stimulation was observed with negatively charged liposomes consisting of phosphatidylcholine (PC), cholesterol and dicetylphosphate (DCP), but not with zwitterionic liposomes, consisting of PC and cholesterol alone. Remarkably, for stimulation of serum IgG responses and induction of an sIgA response, liposomes could be simply mixed with the antigen. Moreover, i.n. administration of empty liposomes up to 48 h prior to i.n. immunization with the subunit antigen also resulted in immune stimulation, indicating that the liposomes did not exert their adjuvant effect by acting as a carrier for the antigen. The liposomal vaccine conferred protection against infection. It is concluded that liposomes, administered i.n., provide a promising adjuvant system for stimulation of antibody responses in general, and mucosal sIgA responses in particular.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7625109     DOI: 10.1016/0264-410x(95)93129-w

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  20 in total

1.  Novel chitosan particles and chitosan-coated emulsions inducing immune response via intranasal vaccine delivery.

Authors:  Takahiro Nagamoto; Yoshiyuki Hattori; Kozo Takayama; Yoshie Maitani
Journal:  Pharm Res       Date:  2004-04       Impact factor: 4.200

2.  Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen.

Authors:  N K Childers; K L Miller; G Tong; J C Llarena; T Greenway; J T Ulrich; S M Michalek
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

3.  A controlled clinical study of the effect of nasal immunization with a Streptococcus mutans antigen alone or incorporated into liposomes on induction of immune responses.

Authors:  N K Childers; G Tong; S Mitchell; K Kirk; M W Russell; S M Michalek
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

Review 4.  Influenza vaccines. A reappraisal of their use.

Authors:  A M Palache
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

5.  Mutants of the Escherichia coli heat-labile enterotoxin with reduced ADP-ribosylation activity or no activity retain the immunogenic properties of the native holotoxin.

Authors:  L de Haan; W R Verweij; I K Feil; T H Lijnema; W G Hol; E Agsteribbe; J Wilschut
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

6.  Mucosal immunoadjuvant activity of liposomes: role of alveolar macrophages.

Authors:  A de Haan; G Groen; J Prop; N van Rooijen; J Wilschut
Journal:  Immunology       Date:  1996-12       Impact factor: 7.397

Review 7.  Novel vaccine development strategies for inducing mucosal immunity.

Authors:  Yoshiko Fujkuyama; Daisuke Tokuhara; Kosuke Kataoka; Rebekah S Gilbert; Jerry R McGhee; Yoshikazu Yuki; Hiroshi Kiyono; Kohtaro Fujihashi
Journal:  Expert Rev Vaccines       Date:  2012-03       Impact factor: 5.217

8.  Intranasal antigen targeting to MHC class II molecules primes local IgA and serum IgG antibody responses in mice.

Authors:  D P Snider; B J Underdown; M R McDermott
Journal:  Immunology       Date:  1997-03       Impact factor: 7.397

Review 9.  Mouse models for the study of mucosal vaccination against otitis media.

Authors:  Albert Sabirov; Dennis W Metzger
Journal:  Vaccine       Date:  2008-02-04       Impact factor: 3.641

10.  Prolonged protection against Intranasal challenge with influenza virus following systemic immunization or combinations of mucosal and systemic immunizations with a heat-labile toxin mutant.

Authors:  Fengmin Zhou; Amanda Goodsell; Yasushi Uematsu; Michael Vajdy
Journal:  Clin Vaccine Immunol       Date:  2009-02-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.